Read more
7:21 PM Β· 10 February 2025

Springworks Therapeutics surges 36% amid acquisition speculation by Merck πŸ”ŽπŸ“ˆ

Merck KGaA (MRCG.DE), the German healthcare and technology company, is in advanced negotiations to acquire U.S.-based Springworks Therapeutics (SWTX.US), a biotech firm specializing in cancer and rare disease treatments. According to sources familiar with the matter, a deal could be finalized in the coming weeks, although terms of the potential agreement have not been disclosed.

Following the news, Springworks' stock surged almost 40% before stabilizing at a 36% gain, reflecting strong investor interest. Springworks, which has a market capitalization of approximately $4 billion, has developed Ogsiveo, a monotherapy drug approved in the U.S. for the treatment of desmoid tumors. The potential acquisition would strengthen Merck's oncology pipeline.

Uncertain Outcome and Industry Interest

While negotiations between Merck and Springworks have progressed, sources caution that other potential buyers may still emerge. Springworks has previously been the subject of takeover speculation, with reports last year suggesting interest from Swiss pharmaceutical firms and AbbVie (ABBV.US).

Merck declined to comment on the discussions but stated that it "continuously assesses options that could support its businesses and strategic positioning." Springworks has also declined to provide a statement regarding the potential deal.

15 May 2026, 7:21 PM

Daily summary: A week closed with declines – is the market starting to fear inflation?

15 May 2026, 5:32 PM

US OPEN: Wall Street Bleeds After Trump's Beijing Visit

15 May 2026, 12:27 PM

Market Wrap: Stocks and metals dip as Trump-Xi summit fails to break Iran deadlock πŸ“‰ (15.05.2026)

14 May 2026, 7:00 PM

Daily Summary: Market euphoria shows no signs of letting up πŸš€

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the ComissΓ£o de Valores MobiliΓ‘rios (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits